The 5th JCA-AACR Special Joint Conference The Latest Advances in Hematological Cancer Research: From Basic Science to Therapeutics
最終更新日：2023年4月28日
Instructions for Oral presenters（134KB）
Instructions for Poster presenters（34KB）
Poster layout（149KB）
Meet the Expert Evening (tentative)（80KB）
The Latest Advances in Hematological Cancer Research:
From Basic Science to Therapeutics
July 13-15, 2016
Tokyo Bay Maihama Hotel Club Resort
1-7, Maihama, Urayasu-shi, Chiba 279-0031, Japan
TEL: +81-47-355-2411
http://www.tbm-clubresort.jp/eng/
April 29, 2016
Abstract Submission Deadline: April 15, 2016
*We have extended the deadline
for abstract submission.
Registration Deadline: June 17, 2016
※We closed the abstract submission
(Required)
Organizing Committee:
JCA
Dr.Takuro Nakamura (The Cancer Institute of JFCR)
Dr.Issay Kitabayashi (National Cancer Center)
Dr.Shigeru Chiba (University of Tsukuba)
AACR
Dr.Jonathan D. Licht (University of Florida Health Cancer Center)
Dr.Ross L. Levine (Memorial Sloan Kettering Cancer Center)
Dr.Catriona Jamieson (Moores UC San Diego Cancer Center)
Program (tentative)
July 13
| Time | Session | Chairperson | Speaker | Title |
|---|---|---|---|---|
| 18:00-18:10 | Welcome Address | |||
| 18:10-19:30 | Keynote | Dr.Licht Dr.Nakamura |
Dr. Jonathan D. Licht (The University of Florida) |
Disordered Histone Methylation in Lymphoid Malignancy |
| Dr.Takuro Nakamura (The Cancer Institute of JFCR) |
Signaling and Transcriptional Networks in Myeloid Leukemogenesis | |||
| 20:00-22:00 | Welcome Party | |||
July 14
| Time | Session | Chairperson | Speaker | Title |
|---|---|---|---|---|
| 8:00-9:30 | 1. Aging and epigenetics in hematopoietic malignancies | Dr.Figueora Dr.Chiba |
Dr.Atsushi Iwama (Chiba University) |
Deregulated Polycomb-group Gene Functions in Hematological Malignancies |
| Dr.Maria E. (Ken) Figueroa (University of Michigan) |
Epigenetic Deregulation in the Aging Hematopoietic Stem Cell | |||
| Dr. Shigeru Chiba(University of Tsukuba) | Aging and TET Dioxygenases in Leukemo/lymphomagenesis | |||
| 9:30-9:50 | Break | |||
| 9:50-11:20 | 2. Myeloproliferative neoplasms and myelodysplastic syndrome | Dr.Levine Dr.Kitamura |
Dr.Ross L. Levine (Memorial Sloan Kettering Cancer Center) |
Role of JAK-STAT Pathway Activation in MPN Pathogenesis and Therapeutic Response |
| Dr.Toshio Kitamura (The University of Tokyo) |
The ASXL1 Mutation and the EZH2 Mutation Induced Myelodysplastic Syndromes in Mice via Distinct Mechanisms | |||
| Dr.Hitoshi Takizawa (Kumamoto University) |
Inflammation-induced Malignant Transformation of Hematopoietic Stem Cell | |||
| 11:20-12:20 | Lunch and Poster View | |||
| 12:20-13:50 | Poster Presentation | |||
| 13:50-15:20 | 3. Recent advances in lymphoma therapeutics | Dr.Melnick Dr.Tobinai | Dr.Ari Melnick (Weill Cornell Medicine) |
Epigenetic Circuits and Their Perturbation in Lymphoid Neoplasms |
| Dr.Kensei Tobinai (National Cancer Center Hospital) |
New Agent Development for Lymphoid Malignancies in Japan | |||
| Dr.Yasuhito Terui (Cancer Institute Hospital of JFCR) |
Recent Advances in Therapeutics for B-cell Lymphoma | |||
| 15:20-15:40 | Break | |||
| 15:40-17:40 | 4. Leukemogenesis: Leukemia stem cell, metabolism and novel targets | Dr.Jamieson Dr.Kitabayashi |
Dr.Atsushi Hirao (Kanazawa University) |
Molecular Mechanism Linking Stem Cell Aging and Tumorigenesis in Hematopoiesis |
| Dr. Catriona H. M. Jamieson (University of California, San Diego) |
Malignant RNA Editing Activation Drives Cancer Stem Cell Self-renewal by Impairing Let-7 Biogenesis | |||
| Dr.Koicji Akashi (Kyushu University) |
TIM-3 and Its Ligand, Galectin-9, Constitute an Autocrine Loop Universally Critical for Development of Human Myeloid Leukemia Stem Cells | |||
| Dr.Issay Kitabayashi (National Cancer Center Research Institute) |
Novel Leukemia Stem Cell-targeted Therapy for Acute Myeloid Leukemia Based on Dual Inhibition of EZH1/EZH2 | |||
| 18:00-19:00 | Meet the Expert (all participants) | |||
| 19:30-21:30 | Banquet | |||
July 15
| Time | Session | Chairperson | Speaker | Title |
|---|---|---|---|---|
| 8:30-10:00 | 5. Genetic and epigenetic alterations in childhood leukemia | Dr.Ferrando Dr.Ito |
Dr.Junko Takita (The Univeristy of Tokyo) |
Integrated Genetic Analysis of Pediatric T-cell Acute Lymphoblastic Leukemia |
| Dr.Adolfo A. Ferrando (Columbia University) |
Oncogenic Signaling Pathways and Mechanisms of Resistance in Acute Lymphoblastic Leukemia | |||
| Dr.Etsuro Ito (Hirosaki University) |
Genetic and Epigenetic Alterations in Acute Megakaryoblastic Leukemia in Down Syndrome | |||
| 10:00-10:20 | Break | |||
| 10:20-11:50 | 6. Genomic landscapes of lymphoid malignancies | Dr.Landau Dr.Mano |
Dr.Seishi Ogawa (Kyoto University) |
A Novel Genetic Mechanism of Evading Anti-tumor Immunity in Multiple Human Cancers |
| Dr.Dan A. Landau (Weill Cornell Medicine) |
Genetic and Epigenetic Determinant of Chronic Lymphocytic Leukemia Evolution | |||
| Dr.Hiroyuki Mano (The University of Tokyo) |
Discovery of DUX4-IGH Fusion-Type Oncogene in B-Cell Acute Lymphoblastic Leukemia of AYA Generation | |||
| 11:50-12:50 | Lunch and Poster View | |||
| 12:50-14:20 | 7. Immunotherapy of hematopoietic neoplasms | Dr.Riddell Dr.Kawakami |
Dr.Yutaka Kawakami (Keio University) |
Current Progress and Future Perspectives in Cancer Immunotherapy: Development of Personalized Combination Immunotherapy |
| Dr.Hiroyoshi Nishikawa (National Cancer Center) |
Critical Role of Regulatory T Cells in Cancer Immunotherapy for Hematologic Malignancies | |||
| Dr.Stanley R. Riddell(Fred Hutchinson Cancer Research Center) | Engineering Safe and Effective T Cell Therapy for Cancer | |||
| 14:20-14:40 | Break | |||
| 14:40-15:40 | 8. Molecular biology and targets of multiple myeloma | Dr.Tiedemann Dr.Furukawa |
Dr.Rodger E. Tiedemann (University of Toronto) |
Intra-Tumor Heterogeneity in Multiple Myeloma and It's Role in Therapeutic Resistance and Relapse |
| Dr.Yusuke Furukawa (Jichi Medical University) |
Epigenetic Mechanisms of Drug Resistance in Multiple Myeloma | |||
| 15:40-15:50 | Closing Remarks | |||
